Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2021 at "European journal of haematology"
DOI: 10.1111/ejh.13697
Abstract: BACKGROUND Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple-class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of… read more here.
Keywords: relapsed refractory; class; triple class; multiple myeloma ... See more keywords